Skip to main
ELMD
ELMD logo

Electromed (ELMD) Stock Forecast & Price Target

Electromed (ELMD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electromed Inc. reported a robust 14.8% increase in homecare revenue, reaching $14.1 million, underscoring enhanced sales representative productivity and effective demand generation initiatives. Furthermore, the company's expanding footprint in the domestic homecare market, coupled with significant growth in distributor and hospital sales—41% and 52% respectively—illustrates its successful market penetration and product adoption. Notably, the increase in SG&A expenses by 17.2% reflects a strategic investment in sales, marketing, and reimbursement efforts, positioning Electromed for future growth amidst a thriving healthcare landscape.

Bears say

The financial analysis indicates a negative outlook for Electromed Inc. due to persistent margin compression and challenges posed by competitive pressures, which could hinder the company's profitability. Additionally, the reduction in sales representative productivity is a significant concern, suggesting a potential decline in revenue generation capabilities. Moreover, delays in the anticipated contributions from Pain Management and Wound Care sectors could further dampen expected growth rates and negatively impact profit margins.

Electromed (ELMD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electromed (ELMD) Forecast

Analysts have given Electromed (ELMD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Electromed (ELMD) has a Strong Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electromed (ELMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.